Baltimore, Maryland, United States
Douglas Falk, Peter Andersen
2018
10
Private company
Series A
34.3
Kiwoom Bio, SCM Life Sciences, Early Light Ventures
Cell Loss
limb-girdle muscular dystrophy
cell therapy
Vita Therapeutics utilizes iPSCs to engineer specific cell types that are designed to replace those that are defective in patients. To deliver these cells we focus on two distinct methodologies: the autologous approach, a patient-specific therapy, and a hypoimmunogenic approach, a universal cell designed to be used for all patients.